en · de · es · fr · pt
tb-500-notes.peptides4962.com › Topic › Identity And Research Background — Hands-On Walkthrough

Identity And Research Background — Hands-On Walkthrough

By Editorial Desk · published 2025-08-18 · last reviewed 2025-09-01 · Topic

Everything below concerns TB-500. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.

Updated 2025-09-01. Numbers and descriptions here follow the published literature rather than marketing material.

Identity and Research Background

TB-500 is a synthetic seven-amino-acid peptide with the sequence LKKTETQ, corresponding to residues 17 through 23 of the protein thymosin beta-4. The N-terminus is typically acetylated in the described form, giving a monoisotopic mass near 888.5 Da and an average mass of about 889 Da. The designation TB-500 is a catalogue label rather than a formal chemical name, and the same sequence appears in the literature under several alternative abbreviations. It is handled as a research reagent rather than a pharmaceutical product.

Thymosin beta-4 is a 43-residue actin-binding protein found in most mammalian cell types, where it participates in cytoskeletal regulation and cell migration. TB-500 represents only a short fragment of that protein and does not include the remaining residues. Whether the isolated fragment reproduces the full range of activities reported for the intact protein remains an open question. Researchers commonly treat the two as related but distinct entities when comparing results.

TB-500 Identity and Molecular Background

TB-500 is a synthetic heptapeptide with the sequence Ac-LKKTETQ. It corresponds to a short N-terminal region of thymosin beta-4, a 43-amino-acid protein found in many cell types. The fragment contains an actin-binding motif, which is one reason it appears in laboratory studies of cell migration and cytoskeletal dynamics. TB-500 is not the full-length protein and is produced as a research chemical rather than an approved therapeutic agent. Its molecular weight is approximately 889 Da.

Several names appear in scientific and commercial contexts for this peptide. The label TB-500 is informal and does not follow standard biochemical nomenclature. Research articles more often describe the compound as a thymosin beta-4 fragment, Tβ4 fragment, or by its sequence Ac-LKKTETQ. Confusing TB-500 with full-length thymosin beta-4 can lead to incorrect assumptions about activity because the fragment lacks the remaining residues of the parent protein. The relationship between fragment and parent protein remains an active area of study.

Tb-500 at a glance

PropertyValueNotes
Molecular formulaC38H68N10O14Acetylated heptapeptide form
Monoisotopic mass888.5 DaAverage mass about 889 Da
AppearanceWhite to off-white solidUsually supplied as lyophilised powder
Solubility classHighly water solubleAlso dissolves in aqueous buffers
Common synonymsTbeta4 fragment, thymosin beta-4 (17-23)Refer to the same sequence

TB-500 Identity and Naming Background

TB-500 is a short synthetic peptide sold under a trade name rather than a systematic chemical name. Suppliers usually describe it as a fragment of thymosin beta-4 and ship it as a lyophilised powder intended for laboratory use. Because the label is commercial, the exact sequence attributed to it is not fully consistent across catalogues, and some listings present a seven-residue peptide while others describe related fragments of similar length. It is not an approved medicine in any major jurisdiction, and it is handled as a research chemical.

Thymosin beta-4 itself is a natural peptide of 43 residues found in many cell types and body fluids. Its best-characterised function is binding and sequestering actin monomers, which influences cytoskeletal dynamics. The sequence most often associated with TB-500, LKKTETQ, corresponds to part of that actin-binding region. A different fragment, Ac-SDKP, is also derived from the same parent peptide and is studied in its own right, which is one reason discussions of thymosin fragments can become confusing. The two are structurally distinct and are not interchangeable.

Related pages on this site

TB-500 Background and Identity

TB-500 is a catalogue name applied to a synthetic peptide related to thymosin beta-4, an actin-binding protein found in most mammalian cells. Suppliers do not use the label consistently: some describe it as the full 43-residue protein, others as a short fragment from the actin-binding region, and others as a related tetrapeptide. Because the name is commercial rather than chemical, two products sold under it may not contain the same molecule. This naming ambiguity is the first point to check in any description of the material.

The most frequently cited identity is a seven-residue fragment with the sequence LKKTETQ, taken from the actin-binding domain of the parent protein. A separate molecule, N-acetyl-seryl-aspartyl-lysyl-proline, often shortened to Ac-SDKP, derives from the same protein's N-terminal region and appears in overlapping literature. Reported molecular masses therefore differ between sources, and a mass value on its own does not establish which fragment is present. Confirmation requires a defined sequence rather than a single number.

Supporting material

In addition, a very thorny issue was that of "replacements", a compensation that Peru would make to Colombian troops for the casualties suffered by them during the war, by exchanging Peruvian citizens and expatriating them to Gran Colombia, exorbitant and inhuman requirement, given that the war had already ended. Given this, Bolívar demobilized most of the Peruvian units (about five thousand who replaced the Gran Colombian casualties) and after the capitulation of Callao, presented on February 10, 1826, the demand to send 6,000 Peruvian recruits to serve Venezuela, sending the first contingents in July, probably no more than 3,000, officially to reinforce the defenses against a possible French invasion (Cien Mil Hijos de San Luis) but in reality it was to confront General Páez, who had started La Cosiata (a separatist movement in Venezuela) and also to demilitarize Peru so that it is not a future threat to its continental projects in the Patria Grande. The troops sent there, due to the distance and lack of knowledge of the language (the majority were indigenous who barely knew Spanish) made desertion or mutiny difficult, many of those sent dying due to the weather and tropical diseases. It is known that some survivors were repatriated of New Granada and Venezuela in 1852 and 1857 respectively. Due to the lifelong and authoritarian constitutions promulgated for Peru and Bolivia, the Liberator would be accused of using his armies to impose political systems, in a republican imperialism, rather than making countries independent.

== Risks == Easy access to sophisticated labs can be a potential biosecurity or bioterrorism threat. Filippa Lentzos, an expert in biological risk and biosecurity, said "there are some pretty crazy people out there ... Barriers are coming down if you want to deliberately do something harmful". Cloud labs say that they review all scheduled experiments and can flag or reject any that appear illegal or dangerous, and that detailed record-keeping makes monitoring what is done easier than in a traditional laboratory.

Once it was established that peptide hormone receptors resided on the plasma membrane of cells, direct studies of the activity of ACTH derivatives that had so long eluded researchers finally became a reality. Hofmann and his colleagues isolated plasma membranes from beef adrenals and were able to conduct structure-activity studies with synthetic analogs of ACTH. Importantly they found that substituting Phenylalanine for theTryptophan residue in position 9 produced a peptide that bound to the ACTH receptor without activating it, i.e. and ACTH antagonist.

Sources: en.wikipedia.org

Supporting material

=== Risk factors === gastrointestinal surgery or other GI procedures electrolyte imbalance (Namely hypokalemia and hypercalcemia) diabetic ketoacidosis (DKA), and other causes of metabolic acidosis hypothyroidism diabetes medications (e.g. opioids or antimuscarinics) severe illness (inflammation with peritonitis) spinal cord injury, those with injury above thoracic vertebra 5 (T5) will have hypomotility problems within the bowel acute intermittent porphyria

== Function == The broad distribution of relaxin-3 fibres/RXFP3 within several key neuronal circuits suggests an ability to modulate a broad range of behaviours. This has been confirmed in a growing number of rodent studies, which demonstrate relaxin-3 is able to modulate arousal, the response to stress, feeding/metabolism and memory; and likely plays a role in the generation/regulation of hippocampal theta rhythm.

== Frequency and population == Sleep disorders including sleep apnea have become an important health issue in the United States. Twenty-two million Americans have been estimated to have sleep apnea, with 80% of moderate and severe OSA cases undiagnosed. OSA can occur at any age, but it happens more frequently in men who are over 40 and overweight.

Sources: en.wikipedia.org

Frequently asked questions

Is TB-500 the same as thymosin beta-4?

No. TB-500 is a short synthetic peptide matching residues 17 to 23 of thymosin beta-4, while the parent protein contains 43 residues. The fragment lacks the rest of the protein sequence, so the two are related but not identical.

What amino acids make up this peptide?

It consists of leucine, lysine, lysine, threonine, glutamic acid, threonine, and glutamine in that order. The N-terminal leucine is usually acetylated in the forms described in catalogues.

How much human data exists for this sequence?

Controlled human data is limited, and most published findings come from cell culture or animal work. This makes it difficult to state clinical effects with confidence.

What is TB-500?

TB-500 is a synthetic heptapeptide corresponding to a fragment of thymosin beta-4. It is used in laboratory research and is not an approved drug.

Network